BSR maintains formal coverage on the development-stage biotechnology companies listed below. Having a company in our coverage universe does not necessarily mean we see them as a good investment. Our opinions on the companies appearing below range from a belief they should be overweight in a diversified biotechnology portfolio to a determination they are not suitable for investment capital. Clicking on the name of the company takes you to brief summary and a link to everything we've published on the company.

Company	Ticker	First coverage
Aegerion Pharmaceuticals	AEGR	July 2012
BioMarin Pharmaceuticals	BMRN	October 2004
Corcept Therapeutics	CORT	September 2004
Dendreon	DNDN	February 2001
Dynavax	DVAX	July 2006
Exelixis	EXEL	January 2011
ImmunoGen	IMGN	October 2009
Medivation	MDVN	January 2011
Oncolytics Biotech	ONCY	June 2005
GenMark Diagnostics	GNMK	February 2008
NuPathe	PATH	March 2011
Raptor Pharmaceuticals	RPTP	July 2008
Repros Therapeutics	RPRX	February 2006
Resverlogix	TSE:RVX	January 2008
Seattle Genetics	SGEN	June 2002